This article isn't saying it doesn't work. It is saying we do not yet have enough evidence to use it outside of a trial setting. The medical field requires a h

This article isn't saying it doesn't work. It is saying we do not yet have enough evidence to use it outside of a trial setting. The medical field requires a high bar of evidence before allowing a treatment for general use. This is what they mean by "first, do no harm". From your linked article: > Several other repurposed medications have shown promise in early smaller trials for example sofosbuvir/daclatasvir, colchicine and remdesivir but the benefit was not seen later in larger trials. This meta-analysis of 24 RCTs in 3328 patients showed a 56% improvement in survival, faster time to clinical recovery and signs of a dose-dependent effect of viral clearance for patients given ivermectin versus control treatment. This benefit needs to be validated in larger confirmatory trials.